Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID-19 severe or critically meta-analysis

Darazam (COVIFERON Interferon beta-1a)
 
NCT04343768
RCTinterferonstandard of careCOVID-19 severe or criticallysome concern
20/20 suggested -63% 122%
Darazam (COVIFERON Interferon beta-1b)
 
NCT04343768
RCTIFN beta-1bstandard of careCOVID-19 severe or criticallysome concern
20/20 inconclusive -43%
Kalil (ACTT-3)
 
NCT04492475
RCTIFN beta-1aplaceboCOVID-19 severe or criticallysome concern
487/482 inconclusive 67% -1%
Rahmani
 
IRCT20100228003449N2
RCTIFN beta-1bstandard of careCOVID-19 severe or criticallysome concern
40/40 conclusif -64%
1 study excluded by filtering options (1 RCT / 0 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).